Skip to Main Content

Advertisement

Skip Nav Destination
Issue Cover
Current Issue
Volume 12,
Issue 8
1 August 2022

About the Journal

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal

Noted This Week

Daiichi Sankyo announced that the FDA granted accelerated approval to trastuzumab deruxtecan (Enhertu) to treat adults with inoperable or metastatic non–small cell lung cancer (NSCLC) whose tumors have HER2 mutations and who have already received a systemic therapy. The decision was based on the DESTINY-Lung02 trial, in which the confirmed overall response rate (ORR) was 58% and the median duration of response (DOR) was 8.7 months among 52 patients. The agency also approved Life Technologies' Oncomine Dx Target Test and Guardant Health's Guardant360 CDx as companion diagnostics.

More Noted This Week, August 5–11   »

Close Modal

or Create an Account

Close Modal
Close Modal